4940 Broadway
Corporate Staff:
Gilbert R. Kaats, PhD
CEO, President and Director
Samuel C. Keith
CIO, Director
Ovidio Pugnale
Director
William W. Luttrell, CPA
Financial Consultant
Robert B. Leckie, ESQ.
Business Development Consultant The Restructuring Body Composition book was published in March 2008 reporting the results
Shirlie Kaats
Secretary, Director
Patricia L. Keith
Treasurer
Michael E. Gale
Operations Manager
Jimmie Mollenkopf
Assistant Operations Manager
Monika Dapilmoto
Research Coordinator
and Nutritionist
Clinical Advisory Board:
Harry A. Croft, MD
Psychiatry and Clinical Research
Larry K. Parker, MD
Obstetrics and Gynecology
William Squires, PhD
Professor of Biology
Texas Lutheran University
Dennis Pullin, MS
Chief Operating Officer
Washington Hospital Center
Washington, DC.
John Wise, PhD
Natural Alternatives International
Microbiology, Biochemistry
Harry G. Preuss, MD
Professor of Medicine
Georgetown University
Reginald McDaniels, MD
Glyco-science Research
Fisher Inst for Medical Research
Kristi L. Hobbs, Director
Alamo City Mercy Foundation
Nutritional/Spiritual Interventions
in Developing Countries
Joel Michalek, PhD
Professor, Center for
Epidemiology/Biostatistics
University of Texas Health
Science Ctr at San Antonio
Raul Bastarrachea, MD
Department of Genetics
SW Fnd Biomedical Research
Portfolio Companies:
Health & Medical Research Inc
HealthTech Development, LLC
HealthTech Products, LLC
Research & Development of Healthcare Products and
Suite 201
San Antonio
Texas 78209
OFC: 210.824.4200
FAX: 210.824.1690
www.ihtglobal.com
March 17, 2008
SUBJECT: Overview of Restructuring Body Composition:
the Glyconutritional Plant Polysaccrides Edition
of what is now a 14-year Longitudinal Trial of Mannatech’s Glyconutritional Plant
Polysaccrides. Mannatech initially provided the following directions to our research team:
1. The studies needed to provide an on-going evaluation of the safety and
efficacy of the Company’s glyconutrients
2. All research should be third-party independent studies. None of the research
team nor their relatives or employees could enroll as a Mannatech Associate
or benefit from product sales other than funding provided for research.
3. Health and Medical Research should continue to conduct a sufficient number
of studies with other companies, including competitive companies, to
support its independent status.
4. The studies should measure “structure & function” changes only and be
devoid of medical and disease claims, or anything that could be construed as
diagnosing, treating, curing or preventing disease.
5. Short-term results should be provided either as technical reports, as
published articles or as contents in a book summarizing the findings.
Although in the initial two years Mannatech, Inc. provided some of the funding for the
trials, it soon became apparent that an increasing number of associates wanted to participate in
the trials by paying for the DEXA and blood tests themselves to monitor their own progress
while taking the product. In essence, they were conducting their own personal “due diligence”
by tracking changes in biomarkers of optimal health using FDA-approved state-of-the-art
technology. The response was so enthusiastic that virtually all of the thousands of DEXA and
blood tests in the database were paid for by the associates with virtually no involvement from
Mannatech, Inc., thereby enhancing Mannatech’s “third-party” relationship with the research.
We have now completing our 14th year of the trials and have accumulated over 8,000
DEXA and blood tests from people taking Mannatech’s supplements. I’m often asked for a
“bottom line” describing our findings of our 14 years of research. In responding, I typically
limit my remarks to the published findings and state that our studies suggest that taking these
glyconutritional plant polysaccharide supplements can:
1. Improve bone strength by increasing bone mineral density
2. Aid in the reduction of excess body fat
3. Help maintain or increase lean (muscle) mass
4. Facilitate or maintain healthy cholesterol and blood lipid levels
5. Increase self-reported quality of life
6. Improve immune health as measured by C-reactive Protein (CRP) levels.
In summary, based on measuring the above biomarkers, taking glyconutritional plant
polysaccharides appears to facilitate improvements in immune health.
All of the above studies are contained in the Restructuring book and are presented in a
slightly edited version of the originally published article. No changes have been made in the
data or in the conclusions drawn from these data. The edits were limited to replacing the
original use of “glyconutrients” with “glyconutritional plant polysaccrides”, a more descriptive
term for the dietary supplements reported in these manuscripts. Changes were also made in the
presentation of the graphics in order to make them more consistent with the style of the
illustrations used throughout this book. If you would like a copy of the book or to receive
updates of current research, call 210-824-4200.
Gilbert R. Kaats, PhD
Integrative Health Technologies, Inc.
Technologies